J&J’s Lenehan Steps Down; Company Vision “Pretty Well Set”
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson has no plans at the present time to fill its president position following the departure of former Consumer Pharmaceuticals & Professional Group Worldwide Chairman James Lenehan
You may also be interested in...
Johnson & Johnson President Brings Extensive McNeil Background To Post
Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years
J&J
William Weldon named vice chairman, overseeing Pharmaceuticals Group, Consumer Pharmaceuticals & Nutritional Products Group, corporate office of science & technology and corporate business development. Group Chairman Robert Savage replaces Weldon as global Rx chairman. Worldwide Medical Devices & Diagnostics Group Chairman James Lenehan also is elevated to vice chairman. Both vice chairmen will report jointly to CEO Ralph Larsen and Senior Vice Chairman Robert Wilson. Management reshuffling may signal a succession race under Larsen. During a recent conference call the CEO discouraged speculation he is considering retiring but acknowledged importance of a clear succession plan
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC